# A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects

> **NCT04802811** · PHASE1 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 37 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** SHR2150；Placebo
- **DRUG:** SHR2150；Placebo
- **DRUG:** SHR2150；Placebo
- **DRUG:** SHR2150；Placebo
- **DRUG:** SHR2150；Placebo

## Key facts

- **NCT ID:** NCT04802811
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-22
- **Primary completion:** 2021-11-10
- **Final completion:** 2021-11-10
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04802811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04802811, "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics ，Pharmacodynamics of Oral SHR2150 in Healthy Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04802811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*